BR0009157B1 - Conjugado antígeno transportador compreendendo um antígeno isolado de S. epidermidis, S. haemolyticus ou S. hominis - Google Patents

Conjugado antígeno transportador compreendendo um antígeno isolado de S. epidermidis, S. haemolyticus ou S. hominis

Info

Publication number
BR0009157B1
BR0009157B1 BRPI0009157-0B1A BR0009157A BR0009157B1 BR 0009157 B1 BR0009157 B1 BR 0009157B1 BR 0009157 A BR0009157 A BR 0009157A BR 0009157 B1 BR0009157 B1 BR 0009157B1
Authority
BR
Brazil
Prior art keywords
antigen
staphylococcus
haemolyticus
hominis
epidermidis
Prior art date
Application number
BRPI0009157-0B1A
Other languages
English (en)
Other versions
BR0009157A (pt
Inventor
Viliam Pavliak
Ali Ibrahim Fattom
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of BR0009157A publication Critical patent/BR0009157A/pt
Publication of BR0009157B1 publication Critical patent/BR0009157B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
BRPI0009157-0B1A 1999-03-19 2000-03-17 Conjugado antígeno transportador compreendendo um antígeno isolado de S. epidermidis, S. haemolyticus ou S. hominis BR0009157B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/272,359 US6936258B1 (en) 1999-03-19 1999-03-19 Staphylococcus antigen and vaccine
PCT/US2000/006922 WO2000056357A2 (en) 1999-03-19 2000-03-17 Staphylococcus antigen and vaccine

Publications (2)

Publication Number Publication Date
BR0009157A BR0009157A (pt) 2002-04-16
BR0009157B1 true BR0009157B1 (pt) 2013-12-24

Family

ID=23039462

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0009157-0B1A BR0009157B1 (pt) 1999-03-19 2000-03-17 Conjugado antígeno transportador compreendendo um antígeno isolado de S. epidermidis, S. haemolyticus ou S. hominis

Country Status (15)

Country Link
US (2) US6936258B1 (pt)
EP (1) EP1162997B1 (pt)
JP (1) JP4656728B2 (pt)
AT (1) ATE320265T1 (pt)
AU (1) AU773226B2 (pt)
BR (1) BR0009157B1 (pt)
CA (1) CA2366433C (pt)
CY (1) CY1105500T1 (pt)
DE (1) DE60026691T2 (pt)
DK (1) DK1162997T3 (pt)
ES (1) ES2261192T3 (pt)
MX (1) MXPA01009476A (pt)
NZ (1) NZ514455A (pt)
PT (1) PT1162997E (pt)
WO (1) WO2000056357A2 (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294177B1 (en) 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1470237A4 (en) * 2001-12-21 2006-02-01 Biosynexus Inc AGAINST PEPTIDOGLYCAN GRAMPOSITIVE BACTERIA MULTIFUNCTIONAL MONOCLONAL ANTIBODIES
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
MX2007008358A (es) * 2005-01-10 2007-09-06 Nabi Biopharmaceuticals Metodo para tratar la infeccion con staphylococcus aureus.
JP5096326B2 (ja) 2005-06-13 2012-12-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ブドウ球菌感染を治療および予防するためのＰａｎｔｏｎ−Ｖａｌｅｎｔｉｎｅロイコシジンの使用
US20080206276A1 (en) * 2005-07-08 2008-08-28 Michael Otto Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections
EP2368569A3 (en) 2006-01-18 2012-05-02 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
NZ570805A (en) 2006-03-30 2011-10-28 Glaxosmithkline Biolog Sa Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
TW200744632A (en) 2006-06-12 2007-12-16 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
US8840906B2 (en) 2007-08-31 2014-09-23 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung disease and conditions
WO2010042481A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
US8101190B2 (en) * 2009-03-03 2012-01-24 Ingen Biosciences Method for diagnosing staphylococcal infections
PL2414387T3 (pl) 2009-04-03 2016-06-30 Univ Chicago Kompozycje i sposoby związane z wariantami białka A (SpA)
PE20110023A1 (es) 2009-06-22 2011-01-31 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
US8974799B2 (en) 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
DK2493498T3 (en) 2009-10-30 2017-05-08 Glaxosmithkline Biologicals Sa Purification of Staphylococcus aureus type 5 and type 8 capsule saccharides
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
KR20130093084A (ko) 2010-07-02 2013-08-21 더 유니버시티 오브 시카고 단백질 Ａ(ＳｐＡ) 변이체와 관련된 조성물 및 방법
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
CA2817973C (en) 2010-10-15 2019-06-25 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
KR20130114210A (ko) 2010-12-22 2013-10-16 와이어쓰 엘엘씨 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
EP2729178A1 (en) 2011-07-08 2014-05-14 Novartis AG Tyrosine ligation process
EP2744517B1 (en) 2011-08-15 2019-03-13 The University of Chicago Compositions and methods related to antibodies to staphylococcal protein a
MX354924B (es) 2011-11-07 2018-03-22 Novartis Ag Molecula portadora que comprende un antigeno spr0096 y un spr2021.
EP2814803A4 (en) 2011-12-14 2015-11-11 Indicator Systems International Inc TRISUBSTITUTED METHYL ALCOHOLS AND POLYMERIZABLE DERIVATIVES THEREOF
EP2841101B1 (en) 2012-04-26 2019-08-07 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
BR112014026861A2 (pt) 2012-04-26 2018-05-15 Univ Chicago antígenos de estafilococos coagulase e métodos de seu uso
RU2724840C2 (ru) 2012-08-16 2020-06-25 Пфайзер Инк. Способы гликоконъюгирования и композиции
PL3363806T3 (pl) 2012-12-20 2022-12-19 Pfizer Inc. Sposób glikokoniugacji
US10125373B2 (en) 2013-01-22 2018-11-13 Arizona Board Of Regents On Behalf Of Arizona State University Geminiviral vector for expression of rituximab
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
CA2918076A1 (en) 2013-07-11 2015-01-15 Novartis Ag Site-specific chemoenzymatic protein modifications
AU2015208821B2 (en) 2014-01-21 2017-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015110940A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
SI3583947T1 (sl) 2014-01-21 2024-01-31 Pfizer Inc. Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
ES2930318T3 (es) 2014-02-14 2022-12-09 Pfizer Conjugados glucoproteicos inmunogénicos
AU2015359503B2 (en) 2014-12-10 2019-05-09 Glaxosmithkline Biologicals Sa Method of treatment
PL3244917T3 (pl) 2015-01-15 2023-07-17 Pfizer Inc. Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
TWI718144B (zh) 2015-05-04 2021-02-11 美商輝瑞股份有限公司 Ｂ型鏈球菌多醣－蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US11246924B2 (en) 2016-04-01 2022-02-15 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
HRP20220573T1 (hr) 2017-01-20 2022-06-10 Pfizer Inc. Imunogeni pripravci, namijenjeni upotrebi u pneumokoknim cjepivima
WO2019183500A1 (en) 2018-03-23 2019-09-26 Hung Chiung Yu Coccidioides antigens and methods of their use
EP3893926A1 (en) 2018-12-12 2021-10-20 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP4203995A1 (en) 2020-08-26 2023-07-05 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
AU2021373358A1 (en) 2020-11-04 2023-06-01 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
JP2024517780A (ja) 2021-05-03 2024-04-23 ファイザー・インク 細菌およびベータコロナウイルス感染症に対するワクチン接種
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2619122B1 (fr) 1987-08-03 1990-03-09 Pasteur Institut Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede
US7279162B1 (en) * 1990-10-22 2007-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
WO1993009811A1 (en) * 1991-11-22 1993-05-27 Univax Biologics, Inc. TYPE I AND TYPE II SURFACE ANTIGENS ASSOCIATED WITH $i(STAPHYLOCOCCUS EPIDERMIDIS)
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
US6294177B1 (en) * 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
AU5804198A (en) 1996-12-20 1998-07-17 Research Foundation Of The City University Of New York A novel pathogenic coccoid organism, (staphylococcus leei), with trophism for gastric mucin
US5965374A (en) * 1997-10-16 1999-10-12 Biowhittaker Technologies, Inc. Glucan-specific assay
ES2321892T3 (es) * 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
US7030101B2 (en) * 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations

Also Published As

Publication number Publication date
CA2366433A1 (en) 2000-09-28
JP4656728B2 (ja) 2011-03-23
CA2366433C (en) 2012-01-03
WO2000056357A3 (en) 2001-02-01
PT1162997E (pt) 2006-07-31
US20050118190A1 (en) 2005-06-02
ATE320265T1 (de) 2006-04-15
EP1162997B1 (en) 2006-03-15
BR0009157A (pt) 2002-04-16
DE60026691T2 (de) 2006-09-07
DK1162997T3 (da) 2006-07-17
JP2002539272A (ja) 2002-11-19
AU773226B2 (en) 2004-05-20
MXPA01009476A (es) 2003-08-19
CY1105500T1 (el) 2010-04-28
DE60026691D1 (de) 2006-05-11
AU3751300A (en) 2000-10-09
EP1162997A2 (en) 2001-12-19
US6936258B1 (en) 2005-08-30
US7531633B2 (en) 2009-05-12
NZ514455A (en) 2003-11-28
ES2261192T3 (es) 2006-11-16
WO2000056357A2 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
BR0009157B1 (pt) Conjugado antígeno transportador compreendendo um antígeno isolado de S. epidermidis, S. haemolyticus ou S. hominis
DK1178824T3 (da) Staphylococcus aureus-antigenholdig helcellevaccine
ATE414532T1 (de) Staphylococcus aureus antigen
BR9406210A (pt) Ensaio de rapamicina
CY1109437T1 (el) ΣΥΝΘΕΣΕΙΣ β-ΓΛΥΚΑΝΩΝ ΚΑΙ ΕΙΔΙΚΩΝ ΑΝΟΣΟΣΦΑΙΡΙΝΩΝ
AU2555297A (en) Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
AU5055593A (en) Antibodies specific for HIV
DK1064303T3 (da) Monoklonale antistoffer, der er specifikke for det prostataspecifikke membranantigens ekstracellulære domæne
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
AU3777989A (en) Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same
SE8505458D0 (sv) Bakteriofager som igenkennings- och identifieringsmedel
AU7336400A (en) Diagnostic assay for type 2 heparin-induced thrombocytopenia
CA2374156A1 (en) Microbial polynucleotides expressed during infection of a host
ES2088464T3 (es) Uso y administracion de enzimas.
IE882250L (en) Monoclonal antibodies and methods for diagnosis of Phytophthora infection
MX9704717A (es) Antigeno, anticuerpos y ensayo de diagnostico para la enfermedad de alzheimer.
CA2141025A1 (en) Anti-mucus glycoprotein monoclonal antibody
FI970299A (fi) Oligomeeriset kantajamolekyylit, joissa on määritetysti sisällytettyjä merkitsinryhmiä ja hapteeneja
CA2156397A1 (en) Rapamycin assay
EP0453419A3 (en) Use of the sp-2 monoclonal antibody for diagnostics and for monitoring of the hiv infection progress
AU7664194A (en) Use of antibodies against beta -2 microglobulin-free, class i hla molecules to provide hiv diagnostic tests as well as compositions having a protective action against hiv infections

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NABI BIOPHARMACEUTICALS (US)

Free format text: ALTERADO DE: NABI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: NABI BIOPHARMACEUTICALS (US)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020100119840/RJ DE 23/12/2010.

B25A Requested transfer of rights approved

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A. (BE)

Free format text: TRANSFERIDO DE: NABI BIOPHARMACEUTICALS

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/12/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)